Syno Capital

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, focused on developing innovative therapies for cardiopulmonary diseases. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor and is currently undergoing Phase III clinical trials for patients experiencing uncontrolled bleeding or requiring urgent surgery. The company is also advancing PB1046, a fusion protein aimed at treating pulmonary arterial hypertension, which is in Phase IIb clinical trials. Additionally, PhaseBio is developing PB6440, an oral agent intended for the treatment of resistant hypertension. Founded in 2002, the company leverages proprietary recombinant biopolymers to enhance the stability and efficacy of its drug candidates.

TCR2 is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to express defined TCR alpha/beta chains. TCR2 was founded by Dr. Patrick Baeuerle and MPM Capital. It has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly affecting the heart, liver, and neurodegenerative conditions. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology, enabling the differentiation of cells into any type found in the body. This technology serves multiple purposes, including drug efficacy testing, medication toxicity screening, and facilitating personalized treatment approaches. The company's product offerings include LifeProfiles, a suite of genetic tests such as FITCODE, which provides insights into fitness-related traits; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

Honor Technology, Inc. operates an online platform that connects in-home caregivers with seniors and their families across several states, including California, Texas, New Mexico, Arizona, Ohio, and Michigan. Founded in 2014 and based in San Francisco, the company provides non-medical home care services aimed at helping older adults live safely and comfortably in their own homes. Honor leverages proprietary technology to screen and match caregivers with seniors based on their specific needs. The platform offers features such as the Honor Frame, which informs seniors about their caregivers and arrival times. Additionally, families can monitor caregiver activities and visit durations. By partnering with local agencies through the Honor Care Network, the company enhances caregiver recruiting, training, and scheduling, supporting a reliable and transparent care experience for older adults.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly affecting the heart, liver, and neurodegenerative conditions. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology, enabling the differentiation of cells into any type found in the body. This technology serves multiple purposes, including drug efficacy testing, medication toxicity screening, and facilitating personalized treatment approaches. The company's product offerings include LifeProfiles, a suite of genetic tests such as FITCODE, which provides insights into fitness-related traits; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

LungLife AI is a molecular diagnostics company that involves in the early detection and treatment of cancer. It uses machine learning and artificial intelligence to enable life-saving early diagnosis of lung cancer. The company focused on transforming cancer diagnosis and management through artificial intelligence (AI) enabled the molecular analysis of cancer biomarkers in blood. The company is developing tests that span all stages of lung cancer from aid in diagnosis for patients with early-stage disease to treatment stratification and monitoring in late-stage lung cancer. The company's diagnostic technology combined with machine learning and image analysis results in workflow efficiencies and improvement in performance. It was founded in 2008 and is headquartered in Thousand Oaks, California.